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ABSTRACT: Autosomal dominant polycystic kidney disease 
(ADPKD) is the most prevalent monogenic renal disease, repre-
senting the fourth cause of end-stage kidney disease. This disorder 
occurs due to mutations in the PKD1 (Polycystic Kidney Disease 
1) or PKD2 (Polycystic Kidney Disease 2) genes, with most of 
the cases caused by mutations in PKD1. The products of these 
genes, polycystin-1 (PC1) and polycystin-2 (PC2), are integral 
membrane glycoproteins that form a complex expressed in the 
surface of primary apical cilia of several cells, including renal 
tubular cells. Such proteins are also expressed in other subcellular 
sites. PC2 functions as a non-selective cation channel with high 
permeability to calcium, while PC1 is thought to function as a 
membrane receptor and likely as an adhesion molecule. Since the 
discovery and characterization of PKD1 and PKD2, the generation 
of genetically-modified animal models has prompted remarkable 
advances in the elucidation of ADPKD pathogenesis and iden-
tification of potential therapeutic targets. Such animals included 
knockout, knockin and spatial and temporal conditional knockout 
models. These progresses allowed the recognition of a complex 
genetic network involved in the modulation of polycystic kidney 
disease and the identification of potential modifiers of ADPKD. 
The mentioned advances also allowed the performance of strategic 
preclinical studies in mouse models orthologous to this disease, 
creating appropriate platforms to support robust clinical trials. The 
generation of composed mutants will likely lead to progressively 
more complex and specific analyses of ADPKD pathogenesis in 
the next decades, with meaningful clinical consequences. More-
over, the technical complexity and speed of generating strategic 
genetically-modified animal models has dramatically improved 
in recent years, considerably expanding the possibilities for the 
coming future. In addition, recently developed in vitro approaches 
such as induced pluripotent stem cells, kidney-on-a-chip and 
kidney organoid technologies are thought to bring robust and 
complementary future inputs to the understanding and therapy 
directed to ADPKD. 
Descritores: Animals, genetically modified; Kidney diseases/
genetics; Polycystic Kidney, Autosomal Dominant.
INTRODUCTION
The expansion of molecular genetics knowledge in the last decades has dramatically modified 
the understanding of mechanisms of life and disease. It is 
worth to note that the obtained invaluable achievements 
in this field were brought to light by an audacious shift 
of the paradigm of scientific thinking that occurred in the 
beginning of the last century. Until then, the classic medical 
science was built based on observations of symptoms 
and tissues abnormalities. While this scientific approach 
resulted in significant medical advances, it was unable to 
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establish deep, detailed disease mechanisms and causative 
links, providing poor substrate to understand pathogenesis 
and limited inputs to therapeutic development. In this 
context, major medical discoveries derived from fortuitous 
experimental findings or ancient traditional knowledge, 
including penicillin, early chemotherapy drugs and acetyl 
salicylic acid. Back then drug development was mainly 
dependent on insights gathered from the observation 
of natural events. Examples of this reality include the 
angiotensin-converting enzyme inhibitors, developed upon 
the recognition of the vasodilator effect determined by a 
serpent venom, and curare, derived from the observation 
of muscular palsy induced by a plant toxin.
In the 1930s, however, advances of genetics, 
microbiology, biochemistry and physics were brought 
together to allow the development of a new revolutionary 
investigative approach, molecular biology. This 
method anchors the understanding of the biological 
phenomena, starting from the characterization and study of 
macromolecules. The knowledge construction, therefore, 
started to be supported and generated upon solid scientific 
data, obtained from rigorous observation and/or controlled 
experimentation. This approach led to consolidation of 
robust platforms of normal and pathogenic molecular 
mechanisms that enabled the development of potentially 
accurate and non-toxic therapeutic interventions.
Interestingly, the initial molecular discoveries 
showed that the fundamental biological processes were 
widely conserved along the phylogenetic evolution. This 
high similarity with other species, in particular with 
superior eukaryotes, allied to ethical limitations of clinical 
studies and high complexity of biological phenomena, 
created the scenario and the need to develop cell and 
animal models of human disease. Since then animal models 
have provided critical contributions to research directed to 
human diseases. The remarkable advances in autosomal 
dominant polycystic kidney (ADPKD) constitute one of 
the histories that document this reality, bringing promising 
perspectives to the field.
ADPKD is the most common monogenic life-
threatening disease, with an estimated prevalence of 
1:400-1000 in the general population1,2. This disease is 
characterized by progressive development of multiple renal 
cysts and a number of extrarenal manifestations. The renal 
phenotype includes a gradual replacement of renal tubules 
by cysts that arise from any nephron segment, although 
those derived from collecting ducts are usually larger and 
more numerous. This process is accompanied for many 
years by reasonably preserved renal function, followed by 
a period of relatively fast decline in glomerular filtration 
rate (GFR). As consequence, end-stage kidney disease 
(ESKD) develops in approximately half of the patients by 
the sixth decade3. The extrarenal manifestations, in turn, 
comprise 1) cardiovascular abnormalities, including mitral 
valve prolapse, intracranial and aortic aneurysms, and left 
ventricular hypertrophy; 2) gastrointestinal abnormalities, 
such as hepatic cysts with marked organ growth in some 
cases, pancreatic cysts, and colon diverticula; and 3) 
additional manifestations, including seminal vesicle and 
epididymal cysts, abdominal hernias and splenic cysts4,5.
The identification of genes mutated in ADPKD 
allowed the characterization of its products and the 
progressive elucidation of genetic, molecular and cellular 
mechanisms involved in this disorder’s pathogenesis. The 
gene mutated in most ADPKD patients, PKD1 (polycystic 
kidney disease 1), was identified and partially characterized 
in 1994, and fully characterized in 19956,7. This gene 
encodes a 14-kb transcript and is related to six pseudogenes 
formed by repeated duplications on chromosome 16. 
In 1996 Mochizuki et al identified the second ADPKD 
causative gene, PKD2 (polycystic kidney disease 2)8. 
Depending on the nature of the analyzed population, 64-
85% of the cases are linked to the PKD1 locus9. This form 
of the disease, referred as ADPKD1, is usually associated 
with a more severe phenotype than ADPKD2, caused by 
mutation in PKD210. 
PKD1 encodes polycystin-1 (PC1), a large 
membrane protein that likely functions as a cell surface 
receptor and as an adhesion molecule11. PKD2, in turn, 
encodes polycystin-2 (PC2), a member of the transient 
receptor protein polycystin (TRPP) family of calcium 
channel proteins12. The two gene products can interact 
intracellularly through coiled-coiled domains and are found 
co-assembled or alone in a variety of cellular locations. 
The interaction between PC1 and PC2 is best characterized 
in primary apical cilia (PAC) of kidney tubular epithelial 
cells. In this organelle, the complex PC1/PC2 appears to act 
as a sensor that regulates ciliary responses to mechanical 
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stimulation, generating calcium influx13,14 (Figure 1). These 
proteins are involved in signaling transduction pathways 
essential for maintenance of differentiated, polarized, 
predominantly reabsorptive tubular epithelial phenotypes, 
as well as for modulation of proliferation and apoptosis15. 
Therefore, mutations in either PKD1 or PKD2 may disrupt 
these fundamental signaling pathways and the mentioned 
cellular features, giving rise to cells with an aberrant 
phenotype. 
Interestingly, many of the genes involved in human 
cystic kidney diseases are expressed in PAC. The PAC, 
classified as non-motile cilium, is a sensory organelle that 
projects itself from the surface of most cells. This structure 
has a fundamental role in cellular signaling, including 
cell growth and differentiation, orientation of planar cell 
polarity and division, cell proliferation and apoptosis16.
Figure 1: Polycystin-1 and polycystin-2 structure. The protein domains are identified in the figure. ER = endoplasmic reticulum; GPS 
= G-protein-coupled receptor proteolytic site; LDL-A = low-density lipoprotein A; PLAT = polycystin-1, lipooxygenase, alpha toxin; 
REJ = receptor for egg-jelly; WSC = cell-wall and stress-response component
Although all ADPKD tubular epithelial cells 
harbor a PKD1 or PKD2 germline mutation in one allele, 
renal cysts develop in less than 1% of the nephrons. The 
understanding of the focal nature of cyst formation in 
ADPKD came with the discovery that cystic lining cells of 
human kidneys and liver display a somatic mutation in the 
previously normal PKD1 or PKD2 allele17,18,19. Based on 
these findings, a ‘two-hit’ model was proposed, where the 
germline mutation constitutes the first hit, while the second 
hit is represented by the mentioned somatic mutation, 
which inactivates or significantly reduces the activity of 
previously normal gene copy. The mechanism of cyst 
formation in ADPKD, however, has been comprehensively 
analyzed in recent years, expanding the proposed two-hit 
model. As discussed ahead, this progress was achieved 
based on the generation of strategic genetically-modified 
mouse models.  
Generation of Genetically-Modified Mouse Models
Despite major contributions brought by in vitro 
molecular models, many issues related to ADPKD 
pathogenesis could not be elucidated in this scenario. In 
vivo models expanded such possibilities, allowing more 
complex, deeper and functional investigation. Since mice 
share 99% of their genes and most of their physiological 
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and pathological features with humans, mouse models 
orthologous to ADPKD are shedding new light on the 
mechanisms of this illness, in addition to providing the 
necessary platform for pre-clinical studies. In this review, 
therefore, we will focus on these genetically-engineered 
mouse models and their hallmark contributions to the 
understanding of ADPKD pathogenesis and the proposal 
of new potential therapeutic interventions. 
Following the complete structural characterization 
of PKD1 and PKD2, mouse models were created with 
targeted mutations to the corresponding mouse orthologues, 
Pkd1 and Pkd2. Gene targeting is widely used to inactivate 
a gene (knockout), but it also can be used to insert point 
mutations, micro-deletions or exogenous DNA insertions 
at specific loci and genomic positions. This technique was 
anchored on the discovery of homologous recombination 
and the isolation of murine embryonic stem cells (ES 
cells)20. This process begins with the construction of a 
vector containing the modified gene sequence, selection 
markers and homologous DNA flanking sequences. The 
targeting vector is then added to ES culture cells and, 
by homologous recombination, the engineered construct 
finds the targeted gene and recombination takes place 
within the homologous sequences. Positive and negative 
selection is used to enrich for ES cells that incorporated the 
modified DNA sequence in the correct position. Following 
appropriate selection, ES cells that incorporated the vector 
are clone-expanded in culture (Figure 2A). These ES cells 
are injected into blastocysts, which are implanted into 
foster mothers to generate chimeric mice able to transmit 
the mutant gene to their progeny. To facilitate isolation of 
the desired progeny, the ES cells and recipient blastocysts 
are derived from mice with different coat colors, associated 
with distinct alleles. Because of this cellular mixing, the 
resultant offspring is called chimeric; many of its cells are 
derived from the original blastocyst while part of its cells 
are derived from recombinant ES cells. If the gonads of 
the chimeric mice were derived from ES cells, its breeding 
with normal mouse will yield offsprings with the coat color 
corresponding to the ES cells and heterozygous for the 
modified gene (Figure 2B). 
Figure 2: Generation of gene-targeted mice. A) Construction of targeting vector containing the modified gene sequence, selection markers 
and homologous DNA flanking sequences. The vector is added to ES culture and recombination takes place within the homologous 
sequences. Positive and negative selection is used to enrich for ES cells that incorporated the modified gene in the correct position; B) 
The modified ES cells are injected into blastocysts, which are implanted into foster mothers to generate chimeric mice able to transmit 
the mutant gene to their progeny. ES cells = embryonic stem cells, Neor = neomycin-resistance gene (positive selection marker), TK= 
thymidine kinase (negative selection marker)
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More recently, the conditional Cre-LoxP system 
has been used to inactivate or activate genes of interest 
in a spatial and temporal manner. Derived from the P1 
bacteriophage, Cre is a site-specific DNA recombinase (Cre) 
that recognizes the 34-bp nucleotide sequence loxP (locus 
of X-over of P1) and catalyzes both intra and intermolecular 
recombination between two loxP sites21. Using homologous 
recombination technology, a targeting vector with loxP 
sites flanking a specific gene region can be incorporated. 
Once Cre is expressed, the region of DNA placed between 
two loxP sites will be excised. For conditional inactivation 
of a given gene, tissue-specific and inducible promoters 
can be used to drive Cre expression. Reporter Cre strains 
have been recently engineered to express a reporter gene 
following the removal of a loxP-flanked STOP cassette, 
marking cell lineages that can be targeted with a given Cre 
line. This methodology can be applied for directing lacZ or 
GFP driving the expression of the β-galactosidase and green 
fluorescent protein, respectively, allowing the identification 
of the cell recombination promoted by Cre activity.
Conditional knockout models are particularly 
important to study ADPKD due to phenotype specificities 
yielded by Pkd1 and Pkd2 inactivation. Along this line, 
the Jackson Laboratories currently offer more than 300 
Cre transgenic mouse strains with different promoters 
and site of expression, bringing huge possibilities to study 
unresolved questions related to ADPKD pathogenesis.  
Orthologous Mouse Models: Contributions to 
Elucidation of ADPKD Pathogenesis and Pre-Clinical 
Studies
Cystogenesis
In a short period of time, several Pkd1 and 
Pkd2 mouse lines have been established with null 
or truncating mutations (Pkd1+/- and Pkd2+/-)22-31. As 
expected, homozygous null mutant mice are embryonic 
lethal and develop severely cystic kidneys in utero. The 
heterozygotes, in turn, developed few cysts later in life, 
mainly in the liver. Further evidence comes from a mouse 
line carrying an unstable allele (Pkd2WS25) that is prone 
to genomic rearrangement and consequent generation 
of a null or wild-type allele29. Compound heterozygous 
Pkd2WS25/- mice, representing an authentic animal model 
of human ADPKD, are born live but develop severely 
polycystic kidneys during adulthood. Interestingly, PC1 
expression was detected in tubules but not in the cyst 
epithelium of Pkd1+/- mice23,29, similarly to what has been 
found in humans17.
Despite strong supporting evidence, the two-hit 
gene mutation model does not sufficiently explain a 
number of observations in humans or mice with ADPKD. 
Hypomorphic homozygous mouse models have reduced 
Pkd1 or Pkd2 expression in all cells in which the gene is 
expressed, or carry a missense mutation that reduces protein 
expression and function32-35. These knockin models are 
perinatally viable and develop cystic phenotype. It must be 
pointed out that cyst formation may occur in a given cell 
when the PC1 or PC2 activity falls below a critical level, 
called “cystogenic threshold”. 
The tissue and/or time-specific conditional knockout 
models enable a well-controlled step-by-step analysis 
of gene inactivation and cyst formation. Using this 
breakthrough technology, studies revealed an important 
change in response to inactivation of both Pkd1 copies 
depending on the life stage of the kidney26,36,37. Using a 
tamoxifen-inducible Pkd1 conditional knockout, Piontek 
et al.36 showed that when Pkd1 inactivation occurred 
before postnatal day 13, the mice developed severely 
cystic kidneys, whereas inactivation after postnatal day 13 
resulted in only late onset cysts. Independently, Lantinga-
van-Leeuwen et al.26 and Takakura et al.37, demonstrated 
that Pkd1 inactivation in adult mice is not sufficient to 
induce massive cyst formation. On the other hand, Pkd1 
inactivation in the first week of life resulted in severely 
cystic phenotype. Taken together, these data support the 
hypothesis that inactivation of Pkd1 would not be sufficient 
to initiate the necessary cell proliferation for significant 
cyst formation in the adult kidney. These data led the 
investigators to propose that the rapid development of cysts 
in the mature kidney might require a third hit in addition to 
the inactivation of both Pkd1 alleles. A subsequent study 
from the same group was able to prove this point, showing 
that renal ischemia/reperfusion (IR) can act as a third hit for 
cyst formation in adult kidneys38. Mice submitted to Pkd1 
inactivation at the age of 5 weeks and to unilateral renal 
IR at 8 weeks developed significantly cystic formation in 
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the kidney submitted to injury, a phenotype not observed 
in the contralateral kidney not submitted to IR. In parallel, 
Bastos et al.39 also showed that Pkd1+/- mouse submitted 
to renal IR developed microcysts 6 weeks after the insult. 
In this context, IR likely represents an additional hit in 
mature kidneys with Pkd1 inactivation, reactivating kidney 
developmental programs and/or promoting increased cell 
proliferation, which can create the cellular environment 
required for rapid and broad cyst formation. 
These results have expanded and improved the 
two-hit model for cystogenesis. In this new scenario, cyst 
formation starts in a given cell when PC1 or PC2 activity 
falls below a critical level. This threshold, however, is 
believed to be strongly dependent on the developmental 
stage and the superimposition of environmental events 
such as renal injury. 
Polycystin-1 cleavage and maturation
An important study showed that recombinant human 
PC1 is cis-autoproteolytically cleaved at the G protein-
coupled receptor proteolytic site domain (GPS) which is 
located just before the beginning of the first transmembrane 
domain40. The cleavage results in two distinct products, the 
N-terminal fragment (NTF) and the C-terminal fragment 
(CTF). To investigate this process in vivo, a Pkd1-knockin 
mouse model (Pkd1v/v) was generated to suppress PC1 
cleavage35. This hypomorphic allele was created by 
inserting the T3041V missense mutation, which modifies 
the GPS-mediated cis-autoproteolysis site without affecting 
the structure and function of the protein. The Pkd1v/v mice 
show a hypomorphic phenotype with lower body growth 
and progressive renal failure from the 8th postnatal day 
on. This phenotype evolves into a severe renal cystic 
involvement and intensely reduced survival, often less than 
25 days. In conclusion, PC1 full length plays a critical role 
during embryonic development, whereas the GPS-cleaved 
PC1 products are essential for postnatal kidney maturation 
and maintenance35.
PC1 maturation depends on its cleavage and post-
translational modifications that results in a glycosylated 
PC1 N-terminal product (PC1-NTR). Interestingly, PC1/
PC2 interaction seems to be essential in this process. 
According to Chapin et al., PC2 expression is crucial to both 
PC1 GPS cleavage and PC1 appearance at the plasma and 
ciliary membrane. Mutations that prevent GPS-dependent 
PC1 cleavage hinder its plasma membrane localization42. A 
later study showed that PC1 and PC2 initially interact in the 
ER before GPS cleavage and that this interaction is central 
to the subsequent PC1 maturation, including exiting from 
the endoplasmic reticulum and cell surface localization. 
In this process, PC2 acts as an essential chaperone for 
PC1 maturation43. A hypomorphic mouse model (Pkd1RC/
RC) that develops gradual cystogenesis displays reduced 
levels of PC1-NTR in renal tissue and urinary exosome-
like vesicles34, supporting an essential role of mature PC1 
in kidney maintenance.
Cardiovascular dysfunction in ADPKD
Several  s tudies  have demonstra ted that 
cardiovascular alterations seem to initiate early in the 
course of ADPKD and constitute a major cause of 
morbidity and mortality in this disease44,45. In this context, 
systemic arterial hypertension (SAH) is present in about 
60% of patients with ADPKD prior to significant renal 
dysfunction46,47 and 10 years earlier than in the general 
population48. The ADPKD cardiovascular phenotype also 
includes increased left ventricular mass49 and idiopathic 
dilated cardiomyopathy50.
In order to test whether cystic disease is the principal 
determinant of hypertension, Fonseca et al investigated 
blood pressure-related phenotypes in two independent 
mouse models orthologous to ADPKD1. The authors 
found that Pkd1+/- (HT) mice, a non-cystic mouse at 
the analyzed age, were normotensive whereas Pkd1cond/
cond:Nestincre, cystic animals with a mosaic pattern of gene 
inactivation (CY), were hypertensive at the ages of 5 and 
10-13 weeks and showed increased kidney expression of 
renin-angiotensin system (RAS) components. Given the 
complementary nature of the evaluated Pkd1-deficient 
models, these results provide key insights into the 
understanding of development of hypertension in ADPKD. 
These data support the concept that distension of cysts 
leads to sectorial vascular compression and consequent 
focal areas of renal ischemia, leading to RAS activation 
and hypertension51. Using the same mouse models, a more 
recent study performed in our laboratory revealed decreased 
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myocardial deformation and systolic function in CY at 5-6 
and 20-24 weeks (wk) of age and in HT noncystic mice at 
5-6 and 10-13 wk, compared to their controls. CYG+ and 
HTG+ hearts presented reduced PC1 expression, increased 
apoptosis and mild fibrosis52. Our findings demonstrate 
an important myocardial dysfunction in different Pkd1-
deficient models suggesting a pivotal role of PC1 in the 
heart.
Genetic interaction in ADPKD and modifier loci
ADPKD represents an imbalance of a complex 
network of genetic interactions. Unraveling such interactions 
is fundamental to understand this disease pathogenesis. To 
address this question, Garcia-Gonzalez et al generated a 
mouse model of autosomal recessive polycystic kidney 
disease (ARPKD) that closely reproduced the renal human 
phenotype. This animal is homozygous for a hypomorphic 
Pkhd1 allele - the mouse orthologue to PKHD1, the gene 
mutated in human ARPKD. When combined with Pkd1 
haploinsufficiency, these mice displayed significant 
worsening of the kidney cystic phenotype, indicating 
genetic interaction between Pkd1 and Pkhd153.
Another key study utilized mice with altered 
expression of genes associated with ADPKD (Pkd1 
and Pkd2), ARPKD (Pkhd1) and autosomal dominant 
polycystic liver disease (Sec63 and Prkcsh)54. In this 
case, decreased activity of Pkd1 or Pkd2, associated with 
reduced function of the other genes worsened the cystic 
phenotype. In contrary, Pkd1 overexpression, but not 
Pkd2, significantly attenuated the cystic burden. These 
data supported the concept of a genetic network, including 
these five genes, and place Pkd1 deficiency as the critical 
player in cystogenesis. 
The PAC subcellular localization of the complex 
PC1/PC2 is critical in cyst formation and growth.  Their 
specific roles in this organelle, however, remain poorly 
understood. To address this question, Ming et al combined 
highly cystic models deficient in Pkd1 or Pkd2 with Ift20 
or Kif3a-deficient mice, creating strategic double-mutant 
animals55. The two last genes are required for maintenance 
of PAC integrity, and the lack of their function typically 
leads to a mildly cystic phenotype in mice. Interestingly, 
the PAC loss in the double mutants resulted in intermediate 
polycystic kidney severity. The severity of the renal 
phenotype was more intense for longer time intervals 
between the losses of polycystins and PAC. This principle 
was verified for developmental and mature kidneys. These 
data indicate that an intact PAC in required for rapid cyst 
growth and support a regulatory role of polycystins in this 
organelle.
As previously mentioned, we have shown that Pkd1-
deficient mice develop cardiac dysfunction52. In the same 
study, double-mutant mice were generated to investigate 
galectin-3 as a potential modifier of the ADPKD cardiac 
phenotype. When Pkd1-deficient mice were placed into 
a homozygous Lgals3 (the gene that encodes galectin-3) 
null allele background, their cardiac phenotype was largely 
rescued. Taken together, our findings demonstrated genetic 
interaction between Pkd1and Lgals3 and revealed the 
potential of galectin-3 as a biomarker and as a target for 
future therapies directed towards heart dysfunction in this 
disease52.
Efforts directed to modifier loci have recently 
included a comprehensive network analysis of gene 
expression, aiming to find a specific signature of ADPKD. 
Using this approach, Menezes et al compared Pkd1 
deficient mice with their normal controls and found quite 
similar expression patterns between the groups between 
post-natal days 12 and 14. The network, however, was 
enriched by metabolic pathways in both groups, suggesting 
that the metabolic state may be an important determinant 
of disease severity56.
Animal models in translational medicine as platforms for 
disease elucidation and clinical trials
Based on whole exome analyses from patients with 
genetically unclear renal cystic diseases, a number of new 
genes have been associated to these disorders. Interestingly, 
the genes FAN1, MRE11, ZNF423, and CEP164, recently 
associated to nephronophthisis-related ciliopathies, are 
involved in DNA damage repair57. Key mutations identified 
in humans may provide valuable insights to unravel 
pathophysiologic mechanisms when reproduced in animal 
models. The generation of a strategic mouse line including 
the human PKD1 hypomorphic variant p.R3277C is a good 
example of such an approach34. Homozygotes for this allele 
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develop a slowly progressive disease that resembles the 
human illness progression, a feature that makes this model 
appropriate for preclinical research.
The recent development of induced pluripotent stem 
cell (iPSC) protocols, in turn, expands the applications of 
animal models. iPSCs are created by genetic reprograming 
somatic cells, allowing investigation of diseases based on 
the generation of specifically-diseased cell lines derived 
from humans. This technology has the advantage of 
transposing the patient genetic background to the research 
setting. Combined with animal models, iPSCs and/or their 
products may provide comprehensive platforms for robust 
and integrated disease research. 
Animal models have become essential to analyze 
pathways altered in cyst-lining cells. This information has 
provided potential targets for therapeutic interventions. 
Reduced activity of the polycystin complex leads to 
defective homeostasis of intracellular calcium (Ca2+) in 
ADPKD cells. Low intra-cytosolic Ca2+ levels stimulate 
adenylyl cyclase 6 and inhibits phosphodiesterases 1 and 
3, favoring intracellular generation and accumulation of 
cAMP (58). In contrast to normal kidney tubular cells, 
the intracellular accumulation of cAMP activates the 
mitogen-activated protein kinase/ERK (MAPK/ERK) 
pathway, promoting cell proliferation and fluid secretion, 
processes that participate in cyst growth59,60. In fact, 
decreased intracellular cAMP induced by a vasopressin V2-
receptor antagonist ameliorated cystic disease progression 
in orthologous and non-orthologous ADPKD murine 
models61-63. On the basis of results obtained in animal 
models, a clinical trial (TEMPO 3:4) was performed 
in ADPKD patients using tolvaptan, a vasopressin V2-
receptor antagonist. Notably, treatment with tolvaptan 
slowed the rate of total kidney volume (TKV) growth and 
the rate of estimated GFR (eGFR) decline64. Recently, the 
European Medicines Agency approved the use tolvaptan 
to slow the progression of ADPKD65. 
Somatostatin is a peptide inhibitory hormone that 
signals via somatostatin receptors to inhibit the generation 
of cAMP. In this context, a recent trial with the long-acting 
somatostatin analog octreotide revealed reduction in TKV 
growth rate in the treated patients compared to the placebo 
group after one year, however significance was no longer 
detected after three years66. These findings provide a 
background for large trials to test the renal protective effect 
of somatostatin analogues in ADPKD.
Since hypertension is a major manifestation 
in ADPKD, with heavy impact on cardiovascular 
morbidity and mortality, and is associated with accelerated 
progression to ESKD, large clinical trials - HALT-PKD 
study-A67 and B68 - were designed to assess potential 
benefits of rigorous blood pressure control and inhibition 
of RAS in ADPKD. Study-A analyzed patients with early 
renal disease, whereas study-B analyzed patients with late 
disease. This study revealed that patients with eGFR>60 
mL/min/1.73 m2 and rigorous BP control (target of 95-
110/60-75-mmHg) displayed a lower annual rate of TKV 
growth, left-ventricular-mass index and albuminuria than 
patients within the same range of renal function submitted 
to conventional BP control (120-130/70-80-mmHg target). 
However, no significant difference in the rate of eGFR 
decline was detected. In addition, combined therapy with 
angiotensin-converting enzyme inhibitor (ACEI) and 
angiotensin receptor blockage showed no renal benefit over 
ACEI alone both for patients with eGFR>60 and between 
25-60 mL/min/1.73 m2.
The mTOR (mammalian target of rapamycin) 
signaling pathway is essential for cell growth, proliferation 
and survival. This pathway is upregulated in cyst-lining 
cells both in patients and in animal models of ADPKD. In 
several pre-clinical studies, mTOR inhibitors ameliorated 
cystic disease progression69-72. Based on this knowledge, 
two independent large clinical trials were performed in 
ADPKD patients using mTOR inhibitors73,74. Such trials 
targeted patients within different ranges of renal function. 
Disappointing results were obtained, however, as mTOR 
inhibition did not show significant effects on disease 
progression in both studies. Dose limiting due to side effects 
may have contributed to the lack of clinical success. 
As observed, biological differences between humans 
and rodents and the complexity of the signaling-pathway 
network related to ADPKD are significant challenges to 
overcome in translating data and information from the 
preclinical to the clinical reality. Combined treatment 
with a number of agents, however, may become an 
effective therapy in the future, since this approach could be 
potentially applied using lower doses, avoiding unwanted 
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adverse effects, while promoting additive beneficial effects. 
Future technologies and perspectives
Possibilities of genetic engineering have become 
more efficient and cost-effective. Notably, the CRISPR/
Cas-9 platform allows the generation of specific knockout 
mice in six months75. This system uses an artificial guide 
RNA complementary to the genomic target sequence 
conjugated to a bacterial protein capable of activating 
caspase 9, therefore leading to DNA cleavage. The 
subsequent DNA non-homologous repair often leads to 
small deletions or inclusions, resulting in loss of gene 
function.
Future perspectives include the generation of 
kidney organoids in 3D cultures, derived from human 
pluripotent stem cells. These cells are submitted to 
systematic differentiation, giving rise to integrated cell 
populations with features of proximal tubule, podocytes 
and endothelium, constituting the organoid. This complex 
structure can reproduce some absorptive and post-injury 
response patterns observed in proximal tubule76. Another 
recently developed technology directed to elucidate 
mechanisms and evaluate potential therapies is the 
kidney-on-a-chip platform77. This modern device allows 
functional assessment of appropriately-organized cell 
preparations reproducing the basic features of the kidney. 
These approaches, however, are still far from reproducing 
the complexity of in vivo models, emphasizing the pivotal 
contributions and need of animals models for the next 
decades. 
Despite the relevant knowledge accumulation in 
ADPKD molecular pathogenesis, the genetic interactions 
and cellular pathways are still largely unknown. The current 
data suggest PKD1 and PKD2 participation in dynamic 
and integrative ways, varying according to the cellular 
and systemic status. Modern technologies allow control 
of the time, tissue and pattern of gene inactivation in a 
relatively fast and available fashion. This setting facilitates 
the generation of animals carrying multiple genetically-
engineered alleles, enabling the investigation of genetic 
interactions in different stages of development, in kidney 
injury, and in other strategic conditions. This approach 
may be allied to the use of modern reporter genes, allowing 
more precise tracking of cellular recombination events. 
The application of network expression platforms, in turn, 
has the potential of returning a comprehensive view and 
critical analysis of alterations in the cell pathway network. 
Such possibilities are likely to favor the identification of 
ADPKD modifier loci and new potential therapeutic targets.
Recently developed in vitro approaches such as the 
kidney-on-a-chip and kidney organoid technologies may 
also provide additional robust and complementary inputs 
to the comprehension and treatment of ADPKD. Along 
these lines, in the next decades the scientific community 
and patients will likely experience a dramatic improvement 
in ADPKD understanding and intervention, provided by 
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